BPA Call 36C24823A0018-36C24824N0316
Award Date
1/1/24
Potential Completion Date
3/12/25
Potential Value
$1.5M
Federal Agency
Veterans Integrated Service Network 8
Awardee
Progenics Pharmaceuticals Inc.
Ultimate Awardee
Lantheus Holdings, Inc.
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
North Billerica, Billerica, MA 01862, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Department of Veterans Affairs (VA) awarded a Firm Fixed Price contract worth $1,732,185.60 to Progenics Pharmaceuticals Inc., a subsidiary of Lantheus Holdings, Inc., for the delivery of PYLARIFY Injection, a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect, localize, and image prostate cancer. This contract is a Blanket Purchase Agreement (BPA) call under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract. The BPA was...
This is a firm fixed price contract awarded by the Defense Health Agency (DHA) to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. and subsidiary of Lantheus Holdings, Inc. The contract, valued at $46,913.36, is for the delivery of PYLARIFY (piflufolastat F-18) injection, a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect, localize, and image prostate cancer. The contract is a Blanket Purchase Agreement (BPA) call, which allows...
This is a federal contract award to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. and subsidiary of Lantheus Holdings, Inc. The contract is for the supply of the radiopharmaceutical PYLARIFY (piflufolastat F-18), a diagnostic agent used in positron emission tomography (PET) scans to detect and image prostate cancer. The contract is a delivery order with a firm fixed price, valued at $3,891,365.28, and has a base period plus three 1-year option years, with a total...
The Department of Veterans Affairs (VA) awarded a Blanket Purchase Agreement (BPA) call with a ceiling value of $902,180.00 to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. and subsidiary of Lantheus Holdings, Inc. The contract is for the procurement of PYLARIFY, a radiopharmaceutical used in positron emission tomography (PET) scans to detect and image prostate cancer. This BPA call was issued under the Pharmaceuticals and Drugs Federal Supply Schedule...
This federal contract award was issued by the Department of Veterans Affairs (VA) to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. and subsidiary of Lantheus Holdings, Inc. The contract, valued at $83,612.11, is for the procurement of PYLARIFY, a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect and image prostate cancer. The contract was awarded under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and is a...
This federal contract award was issued by the Department of Veterans Affairs (VA) to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. and subsidiary of Lantheus Holdings, Inc. The $721,744 firm fixed-price delivery order is for the supply of PYLARIFY (piflufolastat F-18), a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect, localize, and image prostate cancer. The contract is not set aside and is being issued under the...
The U.S. Department of Veterans Affairs (VA) awarded a $1,660,011.20 firm fixed price delivery order contract to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. The contract is for the supply of 80 units of PYLARIFY, a radiopharmaceutical agent used in positron emission tomography (PET) scans to detect and image prostate cancer. This delivery order is part of a larger Indefinite Delivery Vehicle (IDV), likely a Blanket Purchase Agreement (BPA), that Progenics holds...
The Department of Veterans Affairs (VA) awarded Progenics Pharmaceuticals Inc., a subsidiary of Lantheus Holdings, Inc., a $5,040,033.60 firm fixed price delivery order contract to provide PYLARIFY, a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect, localize, and image prostate cancer. This contract is part of the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and is not set aside. The VA, through its various Veterans Integrated Service...
This federal contract award, valued at $855,266.64, was issued by the Department of Veterans Affairs (VA) to Progenics Pharmaceuticals Inc., a subsidiary of Lantheus Holdings, Inc. The contract is for the delivery of PYLARIFY (piflufolastat F-18) injections, a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect and image prostate cancer. The contract is a delivery order under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract, with a...
The U.S. Department of Veterans Affairs (VA) awarded a firm fixed price Blanket Purchase Agreement (BPA) call worth $632,442.60 to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. The contract is for the delivery of PYLARIFY, a radiopharmaceutical diagnostic agent used for positron emission tomography (PET) imaging of prostate cancer. This BPA, which is associated with the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), allows various VA medical...